Ralph T Schermuly

List of Publications by Year
in descending order

201 papers	15,693 citations	19608 61 h-index	18606 119 g-index
206 all docs	206 docs citations	206 times ranked	13504 citing authors

#	Article	IF	Citations
1	Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. European Respiratory Journal, 2022, 59, 2101153.	3.1	13
2	SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension. Circulation, 2022, 145, 916-933.	1.6	21
3	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	2.5	19
4	Inhaled Iloprost Improves Right Ventricular Loadâ€“Independent Contractility in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 111-114.	2.5	10
5	Comparative kinase activity profiling of pathogenic influenza A viruses reveals new anti- and pro-viral protein kinases. Journal of General Virology, 2022, 103, .	1.3	3
6	Targeting Jakâ€“Stat Signaling in Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 100-114.	1.4	37
7	The role of chemokines and chemokine receptors in pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 72-89.	2.7	40
8	Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. British Journal of Pharmacology, 2021, 178, 31-53.	2.7	18
9	Genetic Delivery and Gene Therapy in Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 1179.	1.8	16
10	Experimental Models. , 2021, , 27-52.		0
11	Pulmonary Arterial Hypertension. , 2021, , 1-8.		0
12	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. International Journal of Environmental Research and Public Health, 2021, 18, 1692.	1.2	43
13	Therapeutic Potential of Regorafenibâ€”A Multikinase Inhibitor in Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 1502.	1.8	4
14	The effect of long-term doxycycline treatment in a mouse model of cigarette smoke-induced emphysema and pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L903-L915.	1.3	9
15	Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. International Journal of Environmental Research and Public Health, 2021, 18, 8297.	1.2	6
16	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. Communications Biology, 2021, 4, 1002.	2.0	3
17	Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene. Stem Cell Research, 2021, 55, 102488.	0.3	5
18	Adenylate Kinase 4â€”A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1Î± Signaling Pathways. International Journal of Molecular Sciences, 2021, 22, 10371.	1.8	11

#	Article	IF	Citations
19	Disrupted PI3K subunit p110Î± signaling protects against pulmonary hypertension and reverses established disease in rodents. Journal of Clinical Investigation, 2021, 131, .	3.9	12
20	Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension. International Journal of Environmental Research and Public Health, 2021, 18, 11009.	1.2	2
21	Pulmonary Arterial Hypertension. , 2021, , 1328-1336.		0
22	IRAG1 Deficient Mice Develop PKG1Î² Dependent Pulmonary Hypertension. Cells, 2020, 9, 2280.	1.8	7
23	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. Pulmonary Circulation, 2020, 10, 1-16.	0.8	9
24	Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. International Journal of Molecular Sciences, 2020, 21, 9099.	1.8	5
25	Lack of Contribution of p66shc to Pressure Overload-Induced Right Heart Hypertrophy. International Journal of Molecular Sciences, 2020, 21, 9339.	1.8	4
26	Effect of p53 activation on experimental right ventricular hypertrophy. PLoS ONE, 2020, 15, e0234872.	1.1	6
27	Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice. Respiratory Research, 2020, 21, 136.	1.4	5
28	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	5.1	23
29	Cytochrome P450 epoxygenaseâ€derived 5,6â€epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. Acta Physiologica, 2020, 230, e13521.	1.8	9
30	Yarsagumba is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties. Medicina (Lithuania), 2020, 56, 131.	0.8	5
31	Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status. Scientific Reports, 2020, 10, 888.	1.6	15
32	Lung epithelium damage in COPD â€“ An unstoppable pathological event?. Cellular Signalling, 2020, 68, 109540.	1.7	27
33	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. Basic Research in Cardiology, 2020, 115, 17.	2.5	17
34	Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. Science Advances, 2020, 6, eaba0694.	4.7	39
35	Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 22-28.	2.5	5
36	Reply to Bogaard et al.: Emphysema Isâ€"at the Mostâ€"Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1450-1452.	2.5	4

#	Article	IF	Citations
37	Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nature Communications, 2019, 10, 2987.	5.8	181
38	Depletion of Bone Marrow-Derived Fibrocytes Attenuates TAA-Induced Liver Fibrosis in Mice. Cells, 2019, 8, 1210.	1.8	12
39	Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1550-1554.	2.5	8
40	Pulmonary Vascular Pressure Response to Acute Cold Exposure in Kyrgyz Highlanders. High Altitude Medicine and Biology, 2019, 20, 375-382.	0.5	3
41	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204.	5.8	69
42	Lipids - two sides of the same coin in lung fibrosis. Cellular Signalling, 2019, 60, 65-80.	1.7	22
43	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. Frontiers in Physiology, 2019, 10, 54.	1.3	9
44	LRP1 promotes synthetic phenotype of pulmonary artery smooth muscle cells in pulmonary hypertension. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1604-1616.	1.8	20
45	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. European Respiratory Journal, 2019, 53, 1802445.	3.1	25
46	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1407-1420.	2.5	39
47	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal, 2019, 53, 1801887.	3.1	776
48	Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 346-356.	1.4	20
49	Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. European Respiratory Journal, 2018, 51, 1701024.	3.1	64
50	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulmonary Medicine, 2018, 18, 41.	0.8	46
51	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 373-385.	2.5	78
52	Response to: Comment on â€œEffect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Bandingâ€• BioMed Research International, 2018, 2018, 1-2.	0.9	0
53	The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2018, 5, 179.	1.1	12
54	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. Circulation: Cardiovascular Imaging, 2018, 11, e007653.	1.3	10

#	Article	IF	Citations
55	Nintedanib in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 808-810.	2.5	17
56	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. BioMed Research International, 2018, 2018, 1-9.	0.9	29
57	Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. Experimental Physiology, 2018, 103, 1185-1191.	0.9	14
58	Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. Frontiers in Physiology, 2018, 9, 609.	1.3	42
59	Is the fibroblast growth factor signaling pathway a victim of receptor tyrosine kinase inhibition in pulmonary parenchymal and vascular remodeling?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L248-L252.	1.3	14
60	Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase. JCI Insight, 2018, 3, .	2.3	43
61	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.4	79
62	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. Journal of Heart and Lung Transplantation, 2017, 36, 957-967.	0.3	221
63	Amplified canonical transforming growth factor-Î² signalling via heat shock protein 90 in pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1501941.	3.1	66
64	Enhanced inflammatory cell profiles in schistosomiasisâ€induced pulmonary vascular remodeling. Pulmonary Circulation, 2017, 7, 244-252.	0.8	6
65	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. Circulation Research, 2017, 121, 424-438.	2.0	90
66	Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. Lung, 2017, 195, 489-496.	1.4	24
67	Farnesylation of RhoB: the cancer hypothesis of pulmonary hypertension revisited. Cardiovascular Research, 2017, 113, 249-250.	1.8	1
68	Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. Circulation, 2017, 136, 65-79.	1.6	196
69	Oxidative injury of the pulmonary circulation in the perinatal period: Shortâ€and longâ€term consequences for the human cardiopulmonary system. Pulmonary Circulation, 2017, 7, 55-66.	0.8	24
70	Maintained right ventricular pressure overload induces ventriculararâ€“arterial decoupling in mice. Experimental Physiology, 2017, 102, 180-189.	0.9	18
71	Lung cancerâ€“associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cellâ€“immune cell cross-talk. Science Translational Medicine, 2017, 9, .	5.8	69
72	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 603-614.	1.4	72

#	Article	IF	Citations
73	Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. Cell Stem Cell, 2017, 20, 261-273.e3.	5.2	217
74	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	2.5	113
75	Differential Alterations of the Mitochondrial Morphology and Respiratory Chain Complexes during Postnatal Development of the Mouse Lung. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-22.	1.9	14
76	Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4). PLoS ONE, 2017, 12, e0183166.	1.1	29
77	Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. Physiological Reports, 2017, 5, e13146.	0.7	36
78	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget, 2017, 8, 29613-29624.	0.8	9
79	Relevance of Angiopoietinâ€2 and Soluble Pâ€Selectin Levels in Patients with Pulmonary Arterial Hypertension Receiving Combination Therapy with Oral Treprostinil: A FREEDOMâ€C2 Biomarker Substudy. Pulmonary Circulation, 2016, 6, 516-523.	0.8	7
80	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1137-1149.	3.1	89
81	The prognostic impact of thyroid function in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 1427-1434.	0.3	25
82	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. International Journal of Cardiology, 2016, 216, 85-91.	0.8	28
83	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 63-68.	1.7	19
84	miR-223â€“IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. Cardiovascular Research, 2016, 111, 184-193.	1.8	54
85	Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice. Basic Research in Cardiology, 2016, 111, 22.	2.5	13
86	Nestin-expressing vascular wall cells drive development of pulmonary hypertension. European Respiratory Journal, 2016, 47, 876-888.	3.1	33
87	Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. PLoS ONE, 2016, 11, e0165982.	1.1	10
88	5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. BioMed Research International, 2015, 2015, 1-8.	0.9	62
89	Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1236-1245.	1.1	42
90	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. European Respiratory Journal, 2015, 46, 1084-1094.	3.1	45

#	Article	IF	Citations
91	Loss of Secreted Frizzled-Related Protein-1 Leads to Deterioration of Cardiac Function in Mice and Plays a Role in Human Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 362-372.	1.6	57
92	New potential diagnostic biomarkers for pulmonary hypertension. European Respiratory Journal, 2015, 46, 1390-1396.	3.1	32
93	The F-BAR Protein NOSTRIN Dictates the Localization of the Muscarinic M3 Receptor and Regulates Cardiovascular Function. Circulation Research, 2015, 117, 460-469.	2.0	15
94	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PLoS ONE, 2015, 10, e0129327.	1.1	29
95	Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1Î± depletion or imatinib treatment. Thrombosis and Haemostasis, 2014, 112, 1288-1303.	1.8	18
96	Histological Characterization of Mast Cell Chymase in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Pulmonary Circulation, 2014, 4, 128-136.	0.8	36
97	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smokeâ€“induced Pulmonary Hypertension and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1359-1373.	2.5	80
98	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L986-L995.	1.3	31
99	Impact of S-Adenosylmethionine Decarboxylase 1 on Pulmonary Vascular Remodeling. Circulation, 2014, 129, 1510-1523.	1.6	23
100	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nature Medicine, 2014, 20, 1289-1300.	15.2	233
101	Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. International Journal of Biochemistry and Cell Biology, 2014, 54, 137-148.	1.2	41
102	Protective Effects of 10-nitro-oleic Acid in a Hypoxia-Induced Murine Model of Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 155-162.	1.4	56
103	Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400.	2.5	75
104	Experimental Models. , 2014, , 45-67.		0
105	Mitochondrial Hyperpolarization in Pulmonary Vascular Remodeling. Mitochondrial Uncoupling Protein Deficiency as Disease Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 358-367.	1.4	66
106	Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Research in Cardiology, 2013, 108, 325.	2.5	65
107	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. International Journal of Cardiology, 2013, 167, 2630-2637.	0.8	35
108	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D4-D12.	1.2	465

#	Article	IF	Citations
109	Function of NADPH Oxidase 1 in Pulmonary Arterial Smooth Muscle Cells After Monocrotaline-Induced Pulmonary Vascular Remodeling. Antioxidants and Redox Signaling, 2013, 19, 2213-2231.	2.5	62
110	The role of dimethylarginine dimethylaminohydrolase (<scp>DDAH</scp>) inÂpulmonary fibrosis. Journal of Pathology, 2013, 229, 242-249.	2.1	34
111	Cofilin, a hypoxiaâ€regulated protein in murine lungs identified by 2<scp>DE</scp>: Role of the cytoskeletal protein cofilin in pulmonary hypertension. Proteomics, 2013, 13, 75-88.	1.3	16
112	Mast Cells and Fibroblasts Work in Concert to Aggravate Pulmonary Fibrosis. American Journal of Pathology, 2013, 182, 2094-2108.	1.9	89
113	Inhibition of Overactive Transforming Growth Factorâ€“Î² Signaling by Prostacyclin Analogs in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 733-741.	1.4	39
114	Are Tyrosine Kinase Inhibitors the Better Serotonin Inhibitors?. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 4-5.	2.5	5
115	Classical Transient Receptor Potential Channel 1 in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1451-1459.	2.5	77
116	Anticipated Classes of New Medications and Molecular Targets for Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 226-244.	0.8	40
117	The Peroxisome Proliferatorâ€“Activated Receptor Î²/Î´ Agonist GW0742 has Direct Protective Effects on Right Heart Hypertrophy. Pulmonary Circulation, 2013, 3, 926-935.	0.8	20
118	Sildenafil Potentiates Bone Morphogenetic Protein Signaling in Pulmonary Arterial Smooth Muscle Cells and in Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 34-42.	1.1	64
119	A Molecular Mechanism for Therapeutic Effects of cGMP-elevating Agents in Pulmonary Arterial Hypertension. Journal of Biological Chemistry, 2013, 288, 16557-16566.	1.6	21
120	The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. Experimental Physiology, 2013, 98, 1274-1278.	0.9	9
121	Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. Histology and Histopathology, 2013, 28, 691-9.	0.5	15
122	Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1354-1365.	1.1	108
123	Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 409-419.	2.5	206
124	PAR-2 Inhibition Reverses Experimental Pulmonary Hypertension. Circulation Research, 2012, 110, 1179-1191.	2.0	61
125	Mitochondrial complex II is essential for hypoxia-induced pulmonary vasoconstriction of intra- but not of pre-acinar arteries. Cardiovascular Research, 2012, 93, 702-710.	1.8	20
126	Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 897-908.	2.5	296

#	Article	IF	Citations
127	BDNF/TrkB Signaling Augments Smooth Muscle Cell Proliferation in Pulmonary Hypertension. American Journal of Pathology, 2012, 181, 2018-2029.	1.9	43
128	Activation of TRPC6 channels is essential for lung ischaemiaâ€“reperfusion induced oedema in mice. Nature Communications, 2012, 3, 649.	5.8	162
129	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. PLoS ONE, 2012, 7, e43433.	1.1	100
130	Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. Free Radical Biology and Medicine, 2012, 52, 1033-1042.	1.3	68
131	Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not. Molecular and Cellular Endocrinology, 2012, 349, 145-153.	1.6	14
132	Mechanisms of disease: pulmonary arterial hypertension. Nature Reviews Cardiology, 2011, 8, 443-455.	6.1	605
133	Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs, 2011, 20, 567-576.	1.9	81
134	Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell, 2011, 147, 293-305.	13.5	293
135	Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling. PLoS ONE, 2011, 6, e18136.	1.1	36
136	Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2011, 12, 60.	1.4	66
137	Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. Respiratory Research, 2011, 12, 87.	1.4	17
138	Hypoxia Enhances Platelet-derived Growth Factor Signaling in the Pulmonary Vasculature by Down-Regulation of Protein Tyrosine Phosphatases. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1092-1102.	2.5	73
139	cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases. Circulation, 2011, 123, 1194-1204.	1.6	42
140	Hypoxic Pulmonary Hypertension in Mice with Constitutively Active Plateletâ€Derived Growth Factor Receptorâ€². Pulmonary Circulation, 2011, 1, 259-268.	0.8	44
141	The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. Science Translational Medicine, 2011, 03, 87ra53.	5.8	59
142	A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovascular Research, 2011, 92, 159-168.	1.8	32
143	Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension. PLoS ONE, 2011, 6, e18883.	1.1	36
144	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulmonary Medicine, 2010, 10, 26.	0.8	38

#	Article	IF	Citations
145	Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery, 2010, 9, 956-970.	21.5	118
146	Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 158-167.	2.5	118
147	Pulmonary Vascular Remodeling Correlates with Lung Eggs and Cytokines in Murine Schistosomiasis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 279-288.	2.5	107
148	Dysregulation of the IL-13 Receptor System. A Novel Pathomechanism in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 805-818.	2.5	59
149	Animal models of pulmonary hypertension: role in translational research. Drug Discovery Today: Disease Models, 2010, 7, 89-97.	1.2	11
150	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. Respiratory Research, 2010, 11, 146.	1.4	22
151	Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. Journal of Molecular and Cellular Cardiology, 2010, 49, 598-605.	0.9	56
152	PDGF Receptor and its Antagonists: Role in Treatment of PAH. Advances in Experimental Medicine and Biology, 2010, 661, 435-446.	0.8	55
153	Targeting cancer with phosphodiesterase inhibitors. Expert Opinion on Investigational Drugs, 2010, 19, 117-131.	1.9	123
154	Heme Oxygenase-2 and Large-Conductance Ca2+-activated K+Channels. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 353-364.	2.5	37
155	The Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 683-691.	1.4	93
156	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L658-L665.	1.3	35
157	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	1.2	605
158	Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. Journal of Hypertension, 2009, 27, 322-331.	0.3	52
159	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulmonary Medicine, 2008, 8, 25.	0.8	36
160	Fhl-1, a New Key Protein in Pulmonary Hypertension. Circulation, 2008, 118, 1183-1194.	1.6	79
161	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. Circulation, 2008, 118, 2081-2090.	1.6	139
162	Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 188-196.	2.5	82

#	Article	IF	Citations
163	Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension. Circulation, 2007, 115, 2957-2968.	1.6	46
164	Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature. Circulation Research, 2007, 101, 258-267.	2.0	317
165	Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension. Circulation, 2007, 115, 2331-2339.	1.6	139
166	Hypoxia-induced pulmonary hypertension: Different impact of iloprost, sildenafil, and nitric oxide. Respiratory Medicine, 2007, 101, 2125-2132.	1.3	27
167	Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1072-1078.	1.1	127
168	Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respiratory Research, 2007, 8, 4.	1.4	34
169	Comparison of Pharmacokinetics and Vasodilatory Effect of Nebulized and Infused Iloprost in Experimental Pulmonary Hypertension: Rapid Tolerance Development. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 353-363.	1.2	17
170	In Vivo Characterization of the Novel Imidazopyridine BYK191023 [2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a Potent and Highly Selective Inhibitor of Inducible Nitric-Oxide Synthase. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 181-187.	1.3	12
171	Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. Circulation, 2006, 113, 286-295.	1.6	208
172	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19093-19098.	3.3	273
173	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thrombosis and Haemostasis, 2006, 95, 720-727.	1.8	26
174	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB Journal, 2005, 19, 1175-1177.	0.2	158
175	Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 358-363.	2.5	62
176	Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension. Current Topics in Developmental Biology, 2005, 67, 251-284.	1.0	9
177	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respiratory Research, 2005, 6, 128.	1.4	34
178	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respiratory Research, 2005, 6, 76.	1.4	31
179	Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. Respiratory Research, 2005, 6, 86.	1.4	32
180	Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation, 2005, 115, 2811-2821.	3.9	917

#	Article	IF	Citations
181	Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 39-45.	2.5	230
182	Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension. Circulation Research, 2004, 94, 1101-1108.	2.0	97
183	Prostacyclin and its analogues in the treatment of pulmonary hypertension. , 2004, 102, 139-153.		119
184	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 44, 1488-1496.	1.2	134
185	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 42, 158-164.	1.2	359
186	Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H931-H938.	1.5	34
187	Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1139-1141.	2.5	265
188	Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1358-1365.	2.5	167
189	Pharmacokinetics and Metabolism of Infused versus Inhaled Iloprost in Isolated Rabbit Lungs. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 741-745.	1.3	23
190	Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension. Annals of Internal Medicine, 2002, 136, 515.	2.0	446
191	Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Critical Care Medicine, 2002, 30, 2489-2492.	0.4	69
192	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet, The, 2002, 360, 895-900.	6.3	720
193	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L638-L645.	1.3	59
194	Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L792-L800.	1.3	17
195	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L896-L904.	1.3	23
196	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L1361-L1368.	1.3	37
197	Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 219-225.	1.4	22
198	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H₂O₂?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L683-L690.	1.3	87

#	Article	IF	Citations
199	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L90-L95.	1.3	43
200	Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 600-607.	2.5	369
201	Hypoxic Pulmonary Vasoconstriction-Triggered by an Increase in Reactive Oxygen Species?. Novartis Foundation Symposium, 0, , 196-213.	1.2	12